XBP1, CD138, AND CS1 PEPTIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE PEPTIDES, AND METHODS OF USING SUCH PEPTIDES AND COMPOSITIONS
The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells.
1 - 24 . (canceled)
25 . A method for inducing an immune response in a subject having prostate cancer, the method comprising delivering to the subject a composition comprising a non spliced XBP1 peptide of 35 amino acids or less in length comprising the amino acid sequence of SEQ ID NO:6, a spliced XBP1 peptide of 35 amino acids or less in length and comprising the amino acid sequence of SEQ ID NO:10, and a CD138 peptide of 35 amino acids or less in length and comprising the amino acid sequence of SEQ ID NO:12.
26 . The method of claim 25 , further comprising, after delivering the composition to the subject, determining if an immune response occurred in the subject.
27 . The method of claim 25 or 26 , wherein the subject is a human.
28 - 31 . (canceled)
32 . The method of claim 25 , comprising administering the composition in combination with an additional treatment selected from one or more of a chemotherapeutic agent, ionizing radiation, or an immunotherapy agent.
33 . The method of claim 25 , further comprising administering to the subject one or more immune stimulating agents and/or one or more immune modulating agents.
34 . The method of claim 33 , wherein the one or more immune stimulating agents is selected from an adjuvant comprising carboxymethylcellulose, polyinosinic-polycytidylic acid, and poly-L-lysine double-stranded RNA; an adjuvant comprising a water-and-oil emulsion; and an adjuvant comprising a protein.
35 . The method of claim 33 , wherein the one or more immune modulating agents is selected from an antibody which activates the immune system and an adjuvant.
36 . A method for treating a subject having prostate cancer, the method comprising administering to the subject a composition comprising a non spliced XBP1 peptide of 35 amino acids or less in length comprising the amino acid sequence of SEQ ID NO:6, a spliced XBP1 peptide of 35 amino acids or less in length and comprising the amino acid sequence of SEQ ID NO:10, and a CD138 peptide of 35 amino acids or less in length and comprising the amino acid sequence of SEQ ID NO:12.
37 - 79 . (canceled)
80 . The method of claim 25 , wherein the composition further comprises a CS-1 peptide of 35 amino acids or less in length comprising the amino acid sequence of SEQ ID NO:16.
81 . The method of claim 35 , wherein the adjuvant is a thalidomide derivative.
82 . The method of claim 81 , wherein the adjuvant is lenalidomide.
83 . The method of claim 25 , wherein the subject expresses HLA-A2.
84 . The method of claim 36 , wherein the composition further comprises a CS-1 peptide of 35 amino acids or less in length comprising the amino acid sequence of SEQ ID NO:16.
85 . A method for inducing an immune response in a subject having multiple myeloma, breast cancer, colon cancer, pancreatic cancer, prostate cancer, or leukemia, the method comprising delivering to the subject a composition comprising a non spliced XBP1 peptide of 35 amino acids or less in length comprising the amino acid sequence of SEQ ID NO: 29, a spliced XBP1 peptide of 35 amino acids or less in length and comprising the amino acid sequence of SEQ ID NO: 30, and a CD138 peptide of 35 amino acids or less in length and comprising the amino acid sequence of SEQ ID NO: 31.
86 . The method of claim 85 , wherein the composition further comprises a CS-1 peptide of 35 amino acids or less in length comprising the amino acid sequence of SEQ ID NO: 32.
87 . The method of claim 85 , wherein the multiple myeloma is smoldering multiple myeloma.
88 . The method of claim 85 , wherein the subject expresses HLA-A24.
89 . A method for treating a subject having multiple myeloma, breast cancer, colon cancer, pancreatic cancer, prostate cancer, or leukemia, the method comprising administering to the subject a composition comprising a non spliced XBP1 peptide of 35 amino acids or less in length comprising the amino acid sequence of SEQ ID NO: 29, a spliced XBP1 peptide of 35 amino acids or less in length and comprising the amino acid sequence of SEQ ID NO: 30, and a CD138 peptide of 35 amino acids or less in length and comprising the amino acid sequence of SEQ ID NO: 31.
90 . The method of claim 89 , wherein the composition further comprises a CS-1 peptide of 35 amino acids or less in length comprising the amino acid sequence of SEQ ID NO: 32.
91 . The method of claim 89 , wherein the subject expresses HLA-A24.